Health Condition 1: J452- Mild intermittent asthma Health Condition 2: L80- Vitiligo Health Condition 3: N898- Other specified noninflammatory disorders of vagina Health Condition 4: M199- Osteoarthritis, unspecified site Health Condition 5: K640- First degree hemorrhoids
Conditions
Interventions
None listed
Sponsors
SRMIST
Eligibility
Inclusion criteria
Inclusion criteria: For Hemorrhoids Diagnosed with grade I hemorrhoids. For Vitiligo Diagnosed with non segmental vitiligo stable vitiligo for at least 6 months. For Leucorrhea Clinically diagnosed leucorrhea symptoms present for at least 2 weeks. For Osteoarthritis Clinically diagnosed primary osteoarthritis of the knee Kellgren Lawrence grade 1 to 3 pain score greater or equal to 4 on the visual analog scale VAS. For Asthma Age between 18 and 70 years. Patients with diabetes mellitus or hypertension. Family history of allergy. Occupational asthma or exercise induced asthma.
Exclusion criteria
Exclusion criteria: Haemorrhoids: Known case of rectal tuberculosis or cancer. Anal fissure or infective anal pathologies (cryptitis, proctitis, anal fistula). External haemorrhoids. Patients who underwent surgical procedures for haemorrhoids. Vitiligo: Active infection or comorbidities affecting the skin. Known case of psoriasis, pemphigus, or dermatitis. Leukorrhea: Severe pelvic inflammatory disease or systemic infection. Use of any vaginal treatment within the past 2 weeks. Osteoarthritis: Secondary arthritis or inflammatory joint diseases. Previous knee replacement surgery or intra-articular injections in the last 6 months. Asthma: Pregnant women. Smokers. HBsAg positive patients. Obesity. Patients with a past history of tuberculosis (TB).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Haemorrhoids : Change in Clinical Symptoms; Clinical investigation and Hemorrhoid symptom severity scoring. Osteoarthritis : Change in Clinical Symptoms; Clinical investigation Change in pain scores assessed by the Visual Analog Scale (VAS); Change in physical function assessed by the Western Ontario and McMaster Universities Arthritis Index (WOMAC). Vitiligo : Change in Clinical Symptoms; Change in the Vitiligo Area Scoring Index Leukorrhea : Change in Clinical Symptoms; Reduction in vaginal discharge volume and associated symptoms (e.g., itching, odor) assessed by a Vaginal Discharge Assessment Scale. Asthma : Change in clinical symptoms (cough, wheezing, breathlessness), lung function parameters (FEV1, FVC, Peak Expiratory Flow Rate), asthma control (Asthma Control Test - ACT), and reduction in exacerbations and hospital visits. Timepoint: 0 Month (Baseline) 3 Months (Midpoint/Interim) 6 Months (End of Study/Follow-up) | — |
Secondary
| Measure | Time frame |
|---|---|
| Haemorrhoids : Change in the quality of life will be measured using HEMO-FISS-QoL questionnaires. Leukorrhea , Osteoarthritis : Quality of life assessed by the Short Form Health Survey (SF-36). Vitiligo : Changes in Dermatology Life Quality Index (DLQI). Asthma : Improvement in quality of life (Asthma Quality of Life Questionnaire - AQLQ), reduction in rescue medication use, and changes in inflammatory biomarkers (eosinophil count, FeNO levels). Timepoint: Baseline (0 Month): Prior to initiation of integrated therapy. Midpoint (3 Months): Interim evaluation of clinical progress, symptom control, and quality of life. End of Study (6 Months): Final assessment of clinical outcomes, quality of life, safety, and sustainability of treatment effects. | — |
Countries
India
Contacts
Public ContactDrMG Rajanandh
Interdisciplinary Institute of Indian system of medicine SRMIST
Outcome results
None listed